Short term prognostic role of NT-proBNP in patients after myocardial infarction
- Autori: Rotolo, A.; Ciaramitaro, G.; Farinella, M.; Novo, G.; Andolina, G.; Vitale, F.; Hoffmann, E.; Assennato, P.; Novo, S.; Corrado, E.; Evola, G.; Cospite, V.; Coppola, G.; Augugliaro, S.; Mule', M.; Evola, S.; Caruso, M.
- Anno di pubblicazione: 2009
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: NT-proBNP
- OA Link: http://hdl.handle.net/10447/38384
Aim. The clinical and prognostic role of cardiac natriuretic peptides (CNP) in patients with heart failure is well known; recently, several studies have evaluated the possibility of using CNP to evaluate their potential prognostic role in patients with acute coronary syndromes (ACS). The aim of this study was to evaluate the short term prognostic value of NT-proBNP in 70 patients admitted for ACS. Methods. The authors studied 70 patients with ACS, evaluating, at admission, clinical-anamnestic, instrumental and laboratory characteristics including NT-proBNP plasma levels. Patients were monitored in a 6-month-follow-up to record adverse fatal events and their possible correlation with baseline characteristics. Results. The incidence of adverse events during the follow-up period was 28% (10 patients). In patients with adverse events, the authors observed lower left ventricle ejection fraction (P=0.01), higher prevalence of ST elevation myocardial infarction (P=0.03) and higher NT-proBNP levels (P=0.03), compared to those without adverse events. Moreover, the logistic regression analysis underlined how ST elevation myocardial infarction (P=0.05) and higher NT-proBNP levels (P=0.05) were the only predictive variables for adverse events during the follow up period. Conclusion. This study demonstrates the short term prognostic role of NT-pro BNP in patients admitted for ACS